ELV PE Ratio & Valuation,Is ELV Overvalued

ELV Relative Valuation

ELV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ELV is overvalued; if below, it's undervalued.

Historical Valuation

Elevance Health Inc (ELV) is now in the Fair zone, suggesting that its current forward PE ratio of 13.37 is considered Fairly compared with the five-year average of 13.75. The fair price of Elevance Health Inc (ELV) is between 340.53 to 416.69 according to relative valuation methord.

Relative Value

Fair Zone

340.53-416.69

Current Price：351.90

Fair

13.04

10.07

EV/EBITDA

Elevance Health Inc. (ELV) has a current EV/EBITDA of 10.07. The 5-year average EV/EBITDA is 10.26. The thresholds are as follows: Strongly Undervalued below 8.08, Undervalued between 8.08 and 9.17, Fairly Valued between 11.35 and 9.17, Overvalued between 11.35 and 12.44, and Strongly Overvalued above 12.44. The current Forward EV/EBITDA of 10.07 falls within the Historic Trend Line -Fairly Valued range.

11.30

EV/EBIT

Elevance Health Inc. (ELV) has a current EV/EBIT of 11.30. The 5-year average EV/EBIT is 11.39. The thresholds are as follows: Strongly Undervalued below 8.99, Undervalued between 8.99 and 10.19, Fairly Valued between 12.59 and 10.19, Overvalued between 12.59 and 13.79, and Strongly Overvalued above 13.79. The current Forward EV/EBIT of 11.30 falls within the Historic Trend Line -Fairly Valued range.

0.39

Elevance Health Inc. (ELV) has a current PS of 0.39. The 5-year average PS is 0.62. The thresholds are as follows: Strongly Undervalued below 0.38, Undervalued between 0.38 and 0.50, Fairly Valued between 0.74 and 0.50, Overvalued between 0.74 and 0.86, and Strongly Overvalued above 0.86. The current Forward PS of 0.39 falls within the Undervalued range.

12.14

P/OCF

Elevance Health Inc. (ELV) has a current P/OCF of 12.14. The 5-year average P/OCF is 13.74. The thresholds are as follows: Strongly Undervalued below 8.58, Undervalued between 8.58 and 11.16, Fairly Valued between 16.32 and 11.16, Overvalued between 16.32 and 18.90, and Strongly Overvalued above 18.90. The current Forward P/OCF of 12.14 falls within the Historic Trend Line -Fairly Valued range.

13.13

P/FCF

Elevance Health Inc. (ELV) has a current P/FCF of 13.13. The 5-year average P/FCF is 14.51. The thresholds are as follows: Strongly Undervalued below 9.27, Undervalued between 9.27 and 11.89, Fairly Valued between 17.14 and 11.89, Overvalued between 17.14 and 19.76, and Strongly Overvalued above 19.76. The current Forward P/FCF of 13.13 falls within the Historic Trend Line -Fairly Valued range.

Elevance Health Inc (ELV) has a current Price-to-Book (P/B) ratio of 1.82. Compared to its 3-year average P/B ratio of 2.56 , the current P/B ratio is approximately -28.86% higher. Relative to its 5-year average P/B ratio of 2.71, the current P/B ratio is about -32.76% higher. Elevance Health Inc (ELV) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 5.41%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 6.58% , the current FCF yield is about -100.00% lower.

1.78

P/B

Median3y

2.56

Median5y

2.71

4.70

FCF Yield

Median3y

5.41

Median5y

6.58

Competitors Valuation Multiple

The average P/S ratio for ELV's competitors is , providing a benchmark for relative valuation. Elevance Health Inc Corp (ELV) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 12.33%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ELV decreased by 4.61% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 45.15B to 50.71B.

The secondary factor is the Margin Expansion, contributed 4.93%to the performance.

Overall, the performance of ELV in the past 1 year is driven by Revenue Growth. Which is more sustainable.

12.33%

45.15B → 50.71B

Revenue Growth

4.93%

2.23 → 2.34

Margin Expansion

-21.87%

18.47 → 14.43

P/E Change

-4.61%

368.90 → 351.90

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Elevance Health Inc (ELV) currently overvalued or undervalued?

What is Elevance Health Inc (ELV) fair value?

ELV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Elevance Health Inc (ELV) is between 340.53 to 416.69 according to relative valuation methord.

How does ELV's valuation metrics compare to the industry average?

What is the current P/B ratio for Elevance Health Inc (ELV) as of Dec 17 2025?

As of Dec 17 2025, Elevance Health Inc (ELV) has a P/B ratio of 1.82. This indicates that the market values ELV at 1.82 times its book value.

What is the current FCF Yield for Elevance Health Inc (ELV) as of Dec 17 2025?

As of Dec 17 2025, Elevance Health Inc (ELV) has a FCF Yield of 0.00%. This means that for every dollar of Elevance Health Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Elevance Health Inc (ELV) as of Dec 17 2025?

As of Dec 17 2025, Elevance Health Inc (ELV) has a Forward P/E ratio of 13.37. This means the market is willing to pay $13.37 for every dollar of Elevance Health Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Elevance Health Inc (ELV) as of Dec 17 2025?

As of Dec 17 2025, Elevance Health Inc (ELV) has a Forward P/S ratio of 0.00. This means the market is valuing ELV at $0.00 for every dollar of expected revenue over the next 12 months.

ELV Valuation